190 related articles for article (PubMed ID: 19139476)
21. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
Farzamikia N; Sakhinia E; Afrasiabirad A
Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
[TBL] [Abstract][Full Text] [Related]
22. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.
Schwartz JB; Kane L; Moore K; Wu AH
J Am Med Dir Assoc; 2011 Nov; 12(9):633-8. PubMed ID: 21450231
[TBL] [Abstract][Full Text] [Related]
23. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
[TBL] [Abstract][Full Text] [Related]
24. Expanding role of pharmacogenomics in the management of cardiovascular disorders.
Yip VL; Pirmohamed M
Am J Cardiovasc Drugs; 2013 Jun; 13(3):151-62. PubMed ID: 23579966
[TBL] [Abstract][Full Text] [Related]
25. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
[TBL] [Abstract][Full Text] [Related]
26. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic.
Shaw PB; Donovan JL; Tran MT; Lemon SC; Burgwinkle P; Gore J
J Thromb Thrombolysis; 2010 Aug; 30(2):220-5. PubMed ID: 20204461
[TBL] [Abstract][Full Text] [Related]
27. Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.
Gao L; He L; Luo J; Xu B; Yang J; Zhang YX; Yang T; Li K; Tian JW; Wang HJ; Zhao YS; Lu CY; Zhang WZ; Yin T
Chin Med J (Engl); 2011 Sep; 124(17):2767-70. PubMed ID: 22040439
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand.
Kuanprasert S; Dettrairat S; Palacajornsuk P; Kunachiwa W; Phrommintikul A
J Med Assoc Thai; 2009 Dec; 92(12):1597-601. PubMed ID: 20043560
[TBL] [Abstract][Full Text] [Related]
29. Use of genetic and nongenetic factors in warfarin dosing algorithms.
Wu AH
Pharmacogenomics; 2007 Jul; 8(7):851-61. PubMed ID: 18240910
[TBL] [Abstract][Full Text] [Related]
30. Warfarin pharmacogenetics in a black Zimbabwean cohort: an observational prospective study.
M Hidjo MM; Chikwambi Z; Ngwende G; Matenga JA; Masimirembwa C
Pharmacogenomics; 2023 Jul; 24(10):529-538. PubMed ID: 37435666
[No Abstract] [Full Text] [Related]
31. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
[TBL] [Abstract][Full Text] [Related]
33. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.
Pathare A; Al Khabori M; Alkindi S; Al Zadjali S; Misquith R; Khan H; Lapoumeroulie C; Paldi A; Krishnamoorthy R
J Hum Genet; 2012 Oct; 57(10):665-9. PubMed ID: 22854539
[TBL] [Abstract][Full Text] [Related]
34. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.
van Schie RM; Wadelius MI; Kamali F; Daly AK; Manolopoulos VG; de Boer A; Barallon R; Verhoef TI; Kirchheiner J; Haschke-Becher E; Briz M; Rosendaal FR; Redekop WK; Pirmohamed M; Maitland van der Zee AH
Pharmacogenomics; 2009 Oct; 10(10):1687-95. PubMed ID: 19842940
[TBL] [Abstract][Full Text] [Related]
35. A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement.
Lee SY; Nam MH; Kim JS; Kim JW
J Korean Med Sci; 2007 Jun; 22(3):557-9. PubMed ID: 17596671
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.
Anderson JL; Horne BD; Stevens SM; Grove AS; Barton S; Nicholas ZP; Kahn SF; May HT; Samuelson KM; Muhlestein JB; Carlquist JF;
Circulation; 2007 Nov; 116(22):2563-70. PubMed ID: 17989110
[TBL] [Abstract][Full Text] [Related]
37. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
[TBL] [Abstract][Full Text] [Related]
38. 10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal.
Kurnik D; Loebstein R; Halkin H; Gak E; Almog S
Pharmacogenomics; 2009 Dec; 10(12):1955-65. PubMed ID: 19958094
[TBL] [Abstract][Full Text] [Related]
39. [Oral anticoagulation and pharmacogenetics: importance in the clinical setting].
Benusiglio PR; Desmeules J; de Moerloose P; Dayer P
Rev Med Suisse; 2007 Sep; 3(124):2030, 2033-4, 2036. PubMed ID: 17955831
[TBL] [Abstract][Full Text] [Related]
40. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
